All In Biotech

Drug Trial Radar · NCT07791758

A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma

An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety and Efficacy of LBL-024 Combination Therapy in Patients With Metastatic Colorectal Carcinoma

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 369 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

369

Planned (sponsor's estimate)

Start

Sep 28, 2026

Primary completion

Sep 4, 2030

Study completion Sep 4, 2030

Sponsor

Lead sponsor
Nanjing Leads Biolabs Co.,LtdIndustry
Sponsor type
Industry
Collaborators
Sun Yat-Sen University Cancer Center
First posted
Aug 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multi-center Phase Ib/II clinical trial evaluating the safety and efficacy of LBL-024 in combination with other drugs for the treatment of metastatic colorectal carcinoma (mCRC), aiming to evaluate the safety and efficacy of LBL-024 in combination with other drugs in the treatment of mCRC patients.

Conditions

  • Metastatic Colorectal Carcinoma

Interventions

  • LBL-024 for InjectionDrug

    intravenous infusion.

  • Bevacizumab injectionDrug

    intravenous infusion.

  • Oxaliplatin injectionDrug

    intravenous infusion.

  • Capecitabine tabletsDrug

    Oral.

  • Fruquintinib CapsulesDrug

    Oral.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)
  2. Occurrence of adverse event (AE) and serious adverse event (SAE)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (90 days after drug withdrawal or before the start of new anti-tumor therapy)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • The Sixth Affiliated Hospital Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China · Not yet recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Not yet recruiting

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Not yet recruiting

  • Shanghai GoBroad Cancer Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.